Feinberg Peter 4

What Happened
Peter Feinberg, a director of Immuneering Corp (IMRX), was granted a derivative award covering 33,350 shares on June 11, 2026. The grant is reported at $0.00 per share (derivative/award), meaning no cash was paid at grant; the award will become exercisable/convertible according to the vesting schedule below.

Key Details

• Transaction date: June 11, 2026; reported on Form 4 filed June 11, 2026.
• Instrument/price: Award / derivative reported at $0.00 per share for 33,350 shares.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting (footnote): The award vests and becomes exercisable in equal monthly installments over a one‑year period starting July 11, 2026, and will be fully vested on June 11, 2027 (or upon the 2027 annual meeting, if earlier).
• No indication in the filing of a 10b5-1 plan, tax‑withholding sale, or late filing.

Context
This was a grant/award (not an open‑market purchase or sale). As a derivative award, the shares are subject to the stated vesting schedule and must vest/be exercised per plan terms before becoming freely tradable stock. Grants to directors are common compensation and do not by themselves indicate a buy or sell decision.